Tags

Type your tag names separated by a space and hit enter

Cannabis; adverse effects from an oromucosal spray.
Br Dent J. 2007 Sep 22; 203(6):E12; discussion 336-7.BD

Abstract

BACKGROUND

An oromucosal spray has been developed from the major components of marijuana (cannabis), including tetrahydrocannabinol (THC) and cannabidiol (CBD), in alcohol with a peppermint flavouring, designed to be administered as a spray under the tongue or on the buccal mucosa to relieve pain in multiple sclerosis. Although the available evidence indicates its efficacy in this respect, some patients develop oral burning sensation, stinging or white lesions, probably burns.

OBJECTIVE

To investigate the oral side-effects of oromucosal cannabis spray in multiple sclerosis (MS) patients.

DESIGN

A small open observational study.

SUBJECTS AND METHODS

A series of nine patients with MS who had been using a marijuana oromucosal spray for at least four weeks, were asked to attend for oral examination. Patients were asked whether they had ever experienced symptoms (dryness; bad taste; stinging) associated with use of the spray. A standard oral examination was carried out using a dental light, and the presence of any mucosal lesions recorded. Where mucosal lesions were present, patients were advised to discontinue the spray and re-attend after four weeks for re-examination. For ethical reasons, biopsies were not undertaken at the first visit.

RESULTS

Of nine patients invited to participate, eight attended. All admitted to a stinging sensation on using the oromucosal cannabis spray, and four had visible oral mucosal white lesions in the floor of the mouth.

CONCLUSIONS

Although the white lesions observed were almost certainly burns, resolving or improving on discontinuation of use of the medication, the high alcohol concentration of the oromucosal cannabis spray raises concern in relation to chronic oral use.

Authors+Show Affiliations

Department of Oral Medicine, UCL Eastman Dental Institute, 256 Gray's Inn Road, London, WC1X 8LD. c.scully@eastman.ucl.ac.uk

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17703180

Citation

Scully, C. "Cannabis; Adverse Effects From an Oromucosal Spray." British Dental Journal, vol. 203, no. 6, 2007, pp. E12; discussion 336-7.
Scully C. Cannabis; adverse effects from an oromucosal spray. Br Dent J. 2007;203(6):E12; discussion 336-7.
Scully, C. (2007). Cannabis; adverse effects from an oromucosal spray. British Dental Journal, 203(6), E12; discussion 336-7.
Scully C. Cannabis; Adverse Effects From an Oromucosal Spray. Br Dent J. 2007 Sep 22;203(6):E12; discussion 336-7. PubMed PMID: 17703180.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabis; adverse effects from an oromucosal spray. A1 - Scully,C, Y1 - 2007/08/17/ PY - 2007/03/03/accepted PY - 2007/8/19/pubmed PY - 2007/10/10/medline PY - 2007/8/19/entrez SP - E12; discussion 336-7 JF - British dental journal JO - Br Dent J VL - 203 IS - 6 N2 - BACKGROUND: An oromucosal spray has been developed from the major components of marijuana (cannabis), including tetrahydrocannabinol (THC) and cannabidiol (CBD), in alcohol with a peppermint flavouring, designed to be administered as a spray under the tongue or on the buccal mucosa to relieve pain in multiple sclerosis. Although the available evidence indicates its efficacy in this respect, some patients develop oral burning sensation, stinging or white lesions, probably burns. OBJECTIVE: To investigate the oral side-effects of oromucosal cannabis spray in multiple sclerosis (MS) patients. DESIGN: A small open observational study. SUBJECTS AND METHODS: A series of nine patients with MS who had been using a marijuana oromucosal spray for at least four weeks, were asked to attend for oral examination. Patients were asked whether they had ever experienced symptoms (dryness; bad taste; stinging) associated with use of the spray. A standard oral examination was carried out using a dental light, and the presence of any mucosal lesions recorded. Where mucosal lesions were present, patients were advised to discontinue the spray and re-attend after four weeks for re-examination. For ethical reasons, biopsies were not undertaken at the first visit. RESULTS: Of nine patients invited to participate, eight attended. All admitted to a stinging sensation on using the oromucosal cannabis spray, and four had visible oral mucosal white lesions in the floor of the mouth. CONCLUSIONS: Although the white lesions observed were almost certainly burns, resolving or improving on discontinuation of use of the medication, the high alcohol concentration of the oromucosal cannabis spray raises concern in relation to chronic oral use. SN - 1476-5373 UR - https://www.unboundmedicine.com/medline/citation/17703180/Cannabis L2 - https://doi.org/10.1038/bdj.2007.749 DB - PRIME DP - Unbound Medicine ER -